Skip to content

Association of Transcranial Alternating Current Stimulation with Digital Cognitive Training for Cognitive Remediation in Older Adults

Association of Transcranial Alternating Current Stimulation with Digital Cognitive Training for Cognitive Remediation in Older Adults

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06733714
Enrollment
40
Registered
2024-12-13
Start date
2024-12-02
Completion date
2027-03-01
Last updated
2024-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Disease, Beta-Amyloid, Cognitive Decline, Cognitive Dysfunction, Dementia, Dementia, Vascular, Frontotemporal Degeneration, GFAP, Lewy Body Disease, Mild Cognitive Impairment, Tau Protein

Keywords

tacs, nibs, transcranial alternate current stimulation, mild cognitive impairment, MCI, ALzheimer, Cognition, Elderly, Older Adults, Cognitive enhancement

Brief summary

BACKGROUND Cognitive decline in older adults, especially those who develop Mild Cognitive Impairment and Alzheimer's Disease, currently has limited options of pharmacological treatments, with modest efficacy. Digital Cognitive Training (DCT) and Transcranial Alternating Current Stimulation (tACS) are two promising tools for cognitive remediation in this population. In this exploratory study, we investigate feasibility, tolerability and preliminary effects of the association of both interventions in older adults with cognitive complaints. METHODS Older adults with cognitive complaints are being enrolled for this study, which comprises 5 daily sessions of 30 minutes of DCT using the BrainHQ platform while simultaneously receiving theta tACS (6Hz, 1.6mA) targeting the Left Dorsolateral Prefrontal Cortex.

Detailed description

Our goals in this study are: * To investigate the feasibility and safety of transcranial direct current stimulation (tDCS) adjunctive to cognitive training (CT) in a cohort of individuals diagnosed with mild cognitive impairment (MCI), Subjective Cognitive Decline or Alzheimer's desease in it's initial phase (CDR 1). * To assess the efficacy of this combined intervention in modulating cognitive function, as measured by a comprehensive neuropsychological battery. * To explore the underlying neural mechanisms of this intervention by examining changes in event-related potentials (ERPs), specifically the N200 and P300 components, which are sensitive to cognitive processes and neural plasticity. * To identify potential peripheral biomarkers in serum that may correlate with cognitive decline and response to the intervention. * To determine whether the combined intervention can induce lasting changes in neurophysiological markers, as assessed by repeated ERP measurements. * To examine the relationship between the observed cognitive improvements, alterations in neurophysiological measures, and changes in serum biomarker levels, with the aim of elucidating the biological mechanisms underlying the intervention's effects.

Interventions

DEVICETranscranial Alternating Current Stimulation

An alternate eletric current of 1.6mA in theta frequency is applied in the scalp, using two eletrodes (5x5cm). The eletrodes are located aiming for the left dorsolateral prefrontal Cortex area.

Using a tablet, the participant will do exercises that were designed to stimulate cognitive domains, especially attention and memory. In this case, we use the BrainHQ platform.

Sponsors

Alzheimer's Association
CollaboratorOTHER
Rio de Janeiro State Research Supporting Foundation (FAPERJ)
CollaboratorOTHER_GOV
Conselho Nacional de Desenvolvimento Científico e Tecnológico
CollaboratorOTHER_GOV
Universidade Federal do Rio de Janeiro
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Masking description

A random 5 digits password will be given to the care provider. This password will make the stimulation device enter SHAM mode or true stimulation mode, without the care provider or the patient knowing which mode it will be in. The SHAM mode has the Ramp up and Ramp down periods, so the participant allocated in the control-SHAM group will feel the effects of the eletric current on the scalp for some seconds in the begining and end of each session. Outcome assessors will also not be informed which group the participant is allocated.

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Healthy subjects over 50 years old, with cognitive complaints

Exclusion criteria

* Estimated Intelligence Quotient \<80 * Dependence on psychoactive substances (DSM-V) * Severe psychiatric or neurological disorders * Uncorrected visual/hearing problems * History of syncope for an unexplained reason or seizure less than a year ago * Previous stroke * Use of anticoagulants * Intracranial metallic prosthesis or cardiac pacemaker * Any contraindication to performing tACS

Design outcomes

Primary

MeasureTime frameDescription
MONTREAL COGNITIVE ASSESSMENT (MOCA)1 week after interventionThe MoCA, or Montreal Cognitive Assessment, is a screening tool designed to evaluate global cognitive function, covering domains such as memory, executive function, language, visuospatial abilities, and attention. Scores range from 0 to 30, with higher scores indicating better cognitive performance and a score below 26 often considered indicative of cognitive impairment.

Secondary

MeasureTime frameDescription
Rey-Osterrieth complex figure (ROCF)1 week after interventionThe ROCF evaluates visuospatial constructional abilities, visual memory, and organizational skills. Participants copy a complex figure (copy task) and later reproduce it from memory (recall task). Scores range from 0 to 36, with higher scores representing better performance and lower scores indicating impaired abilities.
Semantic and phonemic verbal fluency1 week after interventionThese tasks measure verbal fluency and executive function by asking participants to generate as many words as possible within a category (semantic fluency) or starting with a specific letter (phonemic fluency) within a limited time. Higher scores indicate better fluency and cognitive flexibility, while lower scores suggest deficits in these areas.
The Rey Auditory Verbal Learning Test (RAVLT)1 week after interventionThe RAVLT assesses verbal memory, including immediate recall, learning, and delayed recall, as well as susceptibility to interference. Scores vary based on the number of correctly recalled items across trials, with higher scores indicating better memory performance and lower scores reflecting poorer memory function.
Visual P300 (Event-Related Potential)1 week after interventionThe P300 is an electrophysiological measure of cognitive processing, typically recorded using EEG during an oddball paradigm. It reflects attention and working memory processes, with shorter latencies and higher amplitudes indicating more efficient neural processing and longer latencies or reduced amplitudes suggesting impairment.
Serum GFAP Analysisbefore interventionGlial fibrillary acidic protein (GFAP) is a biomarker of astrocytic activation and neuroinflammation. Higher serum GFAP levels may indicate glial activation or neurodegeneration, while lower levels are associated with normal brain health.
Five digits test (FDT)1 week after interventionThe FDT assesses attention, processing speed, and executive function. Participants perform tasks involving numerical stimuli under timed conditions. Performance is evaluated based on accuracy and reaction time, with faster and more accurate responses reflecting better cognitive function.
Serum Tau Protein Analysisbefore interventionSerum tau protein levels reflect axonal injury or neurodegeneration. Elevated tau concentrations may indicate pathological processes such as Alzheimer's disease or other neurodegenerative disorders, while normal levels suggest no significant axonal damage.
Prosaccade Task (Eye Tracking)1 week after interventionThis task evaluates basic saccadic eye movement control. Participants are instructed to fixate on a peripheral target as it appears. Key metrics include reaction time, accuracy, and velocity of saccades, with faster and more accurate responses indicating better ocular motor control.
Antisaccade Task (Eye Tracking)1 week after interventionThis task assesses inhibitory control and executive function. Participants must suppress a reflexive saccade to a peripheral target and instead look in the opposite direction. Metrics such as error rates, reaction times, and corrected errors are analyzed, with fewer errors and faster reaction times indicating better inhibitory control and executive function.
Visual Search Task (Eye Tracking):1 week after interventionThis task evaluates visual attention and search efficiency. Participants identify a target among distractors under varying levels of complexity. Performance is measured by reaction time and accuracy, with faster and more precise responses indicating better attentional control and visual search ability.
Serum Beta-Amyloid Analysisbefore interventionThis analysis quantifies beta-amyloid peptides, key biomarkers of Alzheimer's disease pathology. Elevated beta-amyloid levels or an altered ratio of amyloid-beta 42/40 in serum may reflect early neurodegenerative processes, while normal levels are indicative of typical brain function.

Countries

Brazil

Contacts

Primary ContactRogerio Panizzutti, Professor
rogerio.panizzutti@ipub.ufrj.br+55:21-3938-5588
Backup ContactBrunno Costa, PhD student
fc_brunno@hotmail.com+55 31996773008

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026